Is HA-1A cost-effective?
Jennings
M
M
Department of Medicine and Pharmacology, University of Sheffield, England.
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D016470:Bacteremia / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D006090:Gram-Negative Bacteria; D006801:Humans; D008017:Life Expectancy; D016032:Randomized Controlled Trials as Topic